My ePortfolio Register   

Osimertinib suitable for first line EGFRm lung cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.09.17
Views: 810

Dr Suresh Ramalingam - Winship Cancer Institute, Atlanta, USA

Dr Ramalingam talks with ecancer at ESMO 2017 Congress in Madrid about the results of the double blind, randomised FLAURA trial, looking at the use of osimertinib versus the existing standard of care for patients with EGFR mutated lung cancer.

He reports that progression free survival increased from 10.2 months in the control group to 18.9 months for patients who received osimertinib, and recommends it as a new treatment option in this indication

For more on this study, read our news coverage here.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.


Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence